Nadciśnienie tętnicze u kobiet w ciąży cz. 2 – leczenie farmakologiczne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2011
Słowa kluczowe:
nadciśnienie tętnicze, ciąża, leczenie farmakologiczne
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono zasady farmakoterapii i podstawowe grupy leków hipotensyjnych stosowane u kobiet w ciąży. Zalecenia zilustrowano przypadkiem klinicznym.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gryglas , P., & Możeńska , O. (2011). Nadciśnienie tętnicze u kobiet w ciąży cz. 2 – leczenie farmakologiczne . Kardiologia W Praktyce, 4(2), 49-53. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1635
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 2000 Jul, 183(1): S1-S22.
2. Magee L.A., Helewa M., Moutquin J.M. et al.: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada [serial online]. 2008 March, 30: S1-S48.
3. Khalil A., Jauniaux E., Harrington K.: Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet. Gynecol. 2009 Mar, 113(3): 646-54.
4. Toh S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S.: Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am. J. Psychiatry. 2009 Mar, 166(3): 320-8.
5. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H.: First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009 May, 53(5): 812-8.
6. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J.: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2007 Jan 24, CD002252.
7. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. National Guideline Clearinghouse.
8. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S. et al.: Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 2006 Jun 8, 354(23): 2443-51.
9. Caritis S., Sibai B., Hauth J. et al.: Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N. Engl. J. Med. 1998 Mar 12, 338(11): 701-5.
10. Levine R.J., Hauth J.C., Curet L.B. et al.: Trial of calcium to prevent preeclampsia. N. Engl. J. Med. 1997 Jul 10, 337(2): 69-76.
11. Knuist M., Bonsel G.J., Zondervan H.A., Treffers P.E.: Low sodium diet and pregnancy-induced hypertension: a multi-centre randomised controlled trial. Br. J. Obstet. Gynaecol. 1998 Apr, 105(4): 430-4.
12. Sibai B.M., Villar M.A., Bray E.: Magnesium supplementation during pregnancy: a double-blind randomized controlled clinical trial. Am. J. Obstet. Gynecol. 1989 Jul, 161(1): 115-9.
13. Coomarasamy A., Honest H., Papaioannou S. et al.: Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet. Gynecol. 2003 Jun, 101(6): 1319-32.
14. Rumbold A., Duley L., Crowther C.A., Haslam R.R.: Antioxidants for preventing pre-eclampsia. Cochrane Database Syst. Rev. 2008 Jan 23, CD004227.
15. Craici I., Wagner S., Garovic V.D.: Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther. Adv. Cardiovasc. Dis. 2008 Aug, 2(4): 249-59.
16. Aali B.S., Nejad S.S.: Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstet. Gynecol. Scand. 2002 Jan, 81(1): 25-30.
17. Brown M.A., Buddle M.L., Farrell T., Davis G.K.: Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am. J. Obstet. Gynecol. 2002 Oct, 187(4): 1046-50.
18. Chappell L.C., Seed P.T., Briley A.L. et al.: Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999 Sep 4, 354(9181): 810-6.
19. Duley L., Henderson-Smart D.J.: Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst. Rev. 2002, CD001449.
20. Lucas M.J., Leveno K.J., Cunningham F.G.: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N. Engl. J. Med. 1995 Jul 27, 333(4): 201-5.
21. Magee L.A., Cham C., Waterman E.J. et al.: Hydralazine for treatment of severe hypertension in pregnancy: metaanalysis. BMJ 2003 Oct 25, 327(7421): 955-60.
22. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002 Jun 1, 359(9321): 1877-90.
23. Mulrow C.D., Chiquette E., Ferrer R.L.: Management of chronic hypertension during pregnancy. Evidence Report/Technology Assessment No. 14. 2000 Aug, AHRQ Publication No. 00-E011.
24. Podymow T., August P.: Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008 Apr, 51(4): 960-9.
25. Powrie R.O., Rosene-Montella K.: Hypertension and preeclampsia. W: Medical Care of the Pregnant Patient. Lee R., Rosene-Montella L., Barbour L.A., Garner P.R., Keely E. (red.). Philadelphia, Pa: American College of Physicians, 2000: 185-208.
26. Sibai B.M., Mabie W.C., Shamsa F. et al.: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 1990 Apr, 162(4): 960-6; discussion 966-7.
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 1997 Nov 24, 157(21): 2413-46.
28. von Dadelszen P., Magee L.A.: Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J. Obstet. Gynaecol. Can. 2002 Dec, 24(12): 941-5.
29. Levine R.J., Ewell M.G., Hauth J.C. et al.: Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥15 mmHg to a level <90 mmHg in association with proteinuria? Am. J. Obstet. Gynecol. 2000, 183: 787-92.
30. Nadciśnienie tętnicze. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznaj-Derman M. (red.). Medycyna Praktyczna, Kraków 2004.
31. Hnat M.D., Sibai B.M., Caritis S. et al.: National perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am. J. Obstet. Gynecol. 2002, 186: 422-6.
32. Sibai B.M., Caritis S.N., Thom E. et al.: Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal- Fetal Medicine Units. N. Engl. J. Med. 1993, 329: 1213-8.
33. Shennan A., Gupta M., Halligan A. et al.: Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996, 347: 139-42.
34. Working group report on high blood pressure in pregnancy. National Institutes of Health, Washington DC 2000.
35. American College of Obstetricians and Gynecologists. Antenatal corticosteroid therapy for fetal maturation. ACOG Committee Opinion No. 210, American College of Obstetricians and Gynecologists, Washington DC 1998.
36. Effect of antenatal steroids for fetal maturation on perinatal outcomes. NIH Consensus Statement 1994, 12: 1.
37. Staessen J.A., Asmar R., De Buyzere M. et al.: Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit 2001, 6: 355-70.
38. Churchill D., Perry I.J., Beevers D.G.: Ambulatory blood pressure in pregnancy and fetal growth. Lancet 1997, 349: 7-10.
39. Penny J.A., Halligan A.W., Shennan A.H. et al.: Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am. J. Obstet. Gynecol. 1998, 178: 521-6.
40. Perry I.J., Stewart B.A., Brockwell J. et al.: Recording diastolic blood pressure in pregnancy. BMJ 1990, 301: 1198.
41. Higgins J.R., de Swiet M.: Blood pressure measurement and classification in pregnancy. Lancet 2001, 357: 131-5.
42. Expert consensus document on management of cardiovascular diseases during pregnancy. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Eur. Heart J. 2003, 24: 761-81.
43. Moutquin J.M., Garner R.R., Burrows R.F. et al.: Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. Can. Med. Assoc. J. 1997, 157: 907-19.
44. Gilbert J.S., Cox L.A., Mitchell G., Nijland M.J.: Nutrient-restricted fetus and the cardio-renal connection in hypertensive offspring. Expert Rev. Cardiovasc. Ther. 2006, 4: 227-37.
45. Hofmeyr G.J., Atallah A.N., Duley L.: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 2006: CD001059.
46. Olsen S., Secher N.J., Tabor A. et al.: Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000, 107: 382-95.
47. Knight M., Duley L.,Henderson-Smart D.J.,King J.F.: Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst. Rev. 2007: CD000492.
48. Sibai B.M., Mabie W.C., Shamsa F. et al.: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 1990, 162: 960-6.
49. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br. J. Obstet. Gynaecol. 1998, 105: 718-22.
2. Magee L.A., Helewa M., Moutquin J.M. et al.: Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada [serial online]. 2008 March, 30: S1-S48.
3. Khalil A., Jauniaux E., Harrington K.: Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet. Gynecol. 2009 Mar, 113(3): 646-54.
4. Toh S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S.: Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am. J. Psychiatry. 2009 Mar, 166(3): 320-8.
5. Poon L.C., Kametas N.A., Maiz N., Akolekar R., Nicolaides K.H.: First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009 May, 53(5): 812-8.
6. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J.: Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev. 2007 Jan 24, CD002252.
7. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. National Guideline Clearinghouse.
8. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., Dudley J.A., Dyer S., Gideon P.S. et al.: Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med. 2006 Jun 8, 354(23): 2443-51.
9. Caritis S., Sibai B., Hauth J. et al.: Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N. Engl. J. Med. 1998 Mar 12, 338(11): 701-5.
10. Levine R.J., Hauth J.C., Curet L.B. et al.: Trial of calcium to prevent preeclampsia. N. Engl. J. Med. 1997 Jul 10, 337(2): 69-76.
11. Knuist M., Bonsel G.J., Zondervan H.A., Treffers P.E.: Low sodium diet and pregnancy-induced hypertension: a multi-centre randomised controlled trial. Br. J. Obstet. Gynaecol. 1998 Apr, 105(4): 430-4.
12. Sibai B.M., Villar M.A., Bray E.: Magnesium supplementation during pregnancy: a double-blind randomized controlled clinical trial. Am. J. Obstet. Gynecol. 1989 Jul, 161(1): 115-9.
13. Coomarasamy A., Honest H., Papaioannou S. et al.: Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet. Gynecol. 2003 Jun, 101(6): 1319-32.
14. Rumbold A., Duley L., Crowther C.A., Haslam R.R.: Antioxidants for preventing pre-eclampsia. Cochrane Database Syst. Rev. 2008 Jan 23, CD004227.
15. Craici I., Wagner S., Garovic V.D.: Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? Ther. Adv. Cardiovasc. Dis. 2008 Aug, 2(4): 249-59.
16. Aali B.S., Nejad S.S.: Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstet. Gynecol. Scand. 2002 Jan, 81(1): 25-30.
17. Brown M.A., Buddle M.L., Farrell T., Davis G.K.: Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am. J. Obstet. Gynecol. 2002 Oct, 187(4): 1046-50.
18. Chappell L.C., Seed P.T., Briley A.L. et al.: Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999 Sep 4, 354(9181): 810-6.
19. Duley L., Henderson-Smart D.J.: Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst. Rev. 2002, CD001449.
20. Lucas M.J., Leveno K.J., Cunningham F.G.: A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N. Engl. J. Med. 1995 Jul 27, 333(4): 201-5.
21. Magee L.A., Cham C., Waterman E.J. et al.: Hydralazine for treatment of severe hypertension in pregnancy: metaanalysis. BMJ 2003 Oct 25, 327(7421): 955-60.
22. Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002 Jun 1, 359(9321): 1877-90.
23. Mulrow C.D., Chiquette E., Ferrer R.L.: Management of chronic hypertension during pregnancy. Evidence Report/Technology Assessment No. 14. 2000 Aug, AHRQ Publication No. 00-E011.
24. Podymow T., August P.: Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008 Apr, 51(4): 960-9.
25. Powrie R.O., Rosene-Montella K.: Hypertension and preeclampsia. W: Medical Care of the Pregnant Patient. Lee R., Rosene-Montella L., Barbour L.A., Garner P.R., Keely E. (red.). Philadelphia, Pa: American College of Physicians, 2000: 185-208.
26. Sibai B.M., Mabie W.C., Shamsa F. et al.: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 1990 Apr, 162(4): 960-6; discussion 966-7.
27. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 1997 Nov 24, 157(21): 2413-46.
28. von Dadelszen P., Magee L.A.: Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J. Obstet. Gynaecol. Can. 2002 Dec, 24(12): 941-5.
29. Levine R.J., Ewell M.G., Hauth J.C. et al.: Should the definition of preeclampsia include a rise in diastolic blood pressure of ≥15 mmHg to a level <90 mmHg in association with proteinuria? Am. J. Obstet. Gynecol. 2000, 183: 787-92.
30. Nadciśnienie tętnicze. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznaj-Derman M. (red.). Medycyna Praktyczna, Kraków 2004.
31. Hnat M.D., Sibai B.M., Caritis S. et al.: National perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am. J. Obstet. Gynecol. 2002, 186: 422-6.
32. Sibai B.M., Caritis S.N., Thom E. et al.: Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal- Fetal Medicine Units. N. Engl. J. Med. 1993, 329: 1213-8.
33. Shennan A., Gupta M., Halligan A. et al.: Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996, 347: 139-42.
34. Working group report on high blood pressure in pregnancy. National Institutes of Health, Washington DC 2000.
35. American College of Obstetricians and Gynecologists. Antenatal corticosteroid therapy for fetal maturation. ACOG Committee Opinion No. 210, American College of Obstetricians and Gynecologists, Washington DC 1998.
36. Effect of antenatal steroids for fetal maturation on perinatal outcomes. NIH Consensus Statement 1994, 12: 1.
37. Staessen J.A., Asmar R., De Buyzere M. et al.: Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit 2001, 6: 355-70.
38. Churchill D., Perry I.J., Beevers D.G.: Ambulatory blood pressure in pregnancy and fetal growth. Lancet 1997, 349: 7-10.
39. Penny J.A., Halligan A.W., Shennan A.H. et al.: Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? Am. J. Obstet. Gynecol. 1998, 178: 521-6.
40. Perry I.J., Stewart B.A., Brockwell J. et al.: Recording diastolic blood pressure in pregnancy. BMJ 1990, 301: 1198.
41. Higgins J.R., de Swiet M.: Blood pressure measurement and classification in pregnancy. Lancet 2001, 357: 131-5.
42. Expert consensus document on management of cardiovascular diseases during pregnancy. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Eur. Heart J. 2003, 24: 761-81.
43. Moutquin J.M., Garner R.R., Burrows R.F. et al.: Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. Can. Med. Assoc. J. 1997, 157: 907-19.
44. Gilbert J.S., Cox L.A., Mitchell G., Nijland M.J.: Nutrient-restricted fetus and the cardio-renal connection in hypertensive offspring. Expert Rev. Cardiovasc. Ther. 2006, 4: 227-37.
45. Hofmeyr G.J., Atallah A.N., Duley L.: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst. Rev. 2006: CD001059.
46. Olsen S., Secher N.J., Tabor A. et al.: Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000, 107: 382-95.
47. Knight M., Duley L.,Henderson-Smart D.J.,King J.F.: Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst. Rev. 2007: CD000492.
48. Sibai B.M., Mabie W.C., Shamsa F. et al.: A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am. J. Obstet. Gynecol. 1990, 162: 960-6.
49. Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br. J. Obstet. Gynaecol. 1998, 105: 718-22.